Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.

Frontiers in immunology - 1 Jan 2021

Zhou Li, Wang Xuan, Chi Zhihong, Sheng Xinan, Kong Yan, Mao Lili, Lian Bin, Tang Bixia, Yan Xieqiao, Bai Xue, Li Siming, Guo Jun, Cui Chuanliang, Si Lu

Abstract excerpt

Background: Anti-PD-1 monotherapy is the standard therapy for advanced melanoma patients, including those with NRAS mutations. The influence of NRAS mutation on immunotherapy, especially in noncutaneous melanoma, is largely uncharacterized. Materials and Methods: We analyzed clinical data of four clinical trials for advanced melanoma patients treated with anti-PD-1 monotherapy between 2016 and 2019. The impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Kaplan-Meier Estimate

Share to Programmed Cell Death 1 Receptor

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34290710
DOI: 10.3389/fimmu.2021.691032
PMCID: PMC8289467

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.PMID 34290710Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.Semantic proximity Read ↗

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.Semantic proximity Read ↗

Insights into RAS-driven melanoma and its therapeutic implications.Semantic proximity Read ↗

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single centerSemantic proximity Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.